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Summary points
• Hypertension is the leading risk factor for cardiovascular disease, the most common
cause of death worldwide.
• In 2011, the United Nations declared that lessons learned from national human immu-
nodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), tuberculosis,
and malaria programs in low- and middle-income countries should be harnessed for
effective integration of communicable and noncommunicable disease initiatives.
• HIV clinical service delivery facilities offer a platform on which to enhance care by
offering noncommunicable disease interventions.
• Given Malawi’s high prevalence of hypertension, with an estimated one-third of adults
in the country affected, we sought to incorporate hypertension management in HIV
care delivery sites using standardized treatment protocols and patient registries to moni-
tor treatment outcomes.
• The overall aim was to create a reproducible and scalable hypertension management
model for HIV-infected persons that is cost effective and that can be used to inform
national scale-up of hypertension and other chronic disease care models.
• We describe pertinent issues that were raised during the design and implementation of
the program, particularly important for the enhanced care of HIV-infected persons.
Introduction
Hypertension is the leading risk factor for cardiovascular disease (CVD), the most common
cause of death worldwide [1]. Although sub-Saharan Africa (SSA) is among the last regions in
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the world to undergo the epidemiologic transition of mortality from infectious disease to
noncommunicable disease (NCD), there is a high dual burden of communicable and non-
communicable diseases in this region [2,3]. Currently, acquired immunodeficiency syn-
drome (AIDS) is the leading cause of death in SSA [2]. However, with the successful
expansion of access to antiretroviral therapy (ART) in SSA, dramatic reductions in AIDS-
related morbidity and mortality are expected, as seen in high-income countries [4]. As per-
sons living with human immunodeficiency virus (PLHIVs) in SSA gain access to ART and
achieve virologic suppression, they will live longer and experience a similar life expectancy
to HIV-uninfected persons [4]. Thus, comorbidities, such as CVD, will become increasingly
prevalent [5].
PLHIVs are at an increased risk for CVD because of an increased prevalence of tradi-
tional risk factors and nontraditional risk factors (e.g., inflammation) as well as effects of
specific antiretroviral drugs [6]. Given that PLHIVs are at higher risk for CVD [7], the treat-
ment and control of a high-burden, treatable risk factor such as hypertension are important
as an entry point to a more comprehensive approach to CVD management. Hypertension is
common in SSA, with prevalence estimates in the general adult population ranging from
about 15% to 40% [3]. However, the majority of persons with hypertension (60%–90%) are
unaware of their condition, and very few (<5%) have achieved blood pressure control [8].
Therefore, there is a demonstrated need for hypertension screening and control programs
in the region.
The setting: Malawi
Malawi has a government-funded national healthcare service that is free to all Malawians.
Delivery of healthcare occurs at 3 levels: health centers at the local level, regional/rural hospi-
tals one level up, and district hospitals at the highest level. Because of low resources, investiga-
tions are limited, and diagnosis is largely based on clinical presentation. Most laboratory,
imaging, and testing facilities are often only available at the major district hospitals. Malawi
has very few doctors; therefore, clinical officers (who are trained for a minimum of 4 years and
are very experienced practitioners) and medical assistants (who are trained for a minimum of
3 years) are the main healthcare cadre [9].
Malawi has one of the highest HIV prevalence rates (10.6%) among persons aged 15–64
years in the world, and 33% of Malawians aged 25–64 years have high blood pressure (BP) [3].
The President’s Emergency Plan for AIDS Relief (PEPFAR) was responsible for the rapid
growth of ART clinics in Malawi with decentralization of services, which have provided life-
saving ART to over 600,000 PLHIVs at 650 sites nationwide. Although quality HIV programs
exist, there remains a large unmet need in Malawi to improve the quality of healthcare services,
promote early detection, and optimize clinical management of hypertension to reduce illness
and avoid premature deaths. Additionally, while costs are low for routine BP screening during
clinical visits, the HIV clinics in Malawi were not routinely offering these services. The exten-
sive PEPFAR-supported clinic network in Malawi illustrated the potential programmatic
reach for the management of other chronic diseases using HIV as a platform for service deliv-
ery. For these reasons, the Centers for Disease Control and Prevention (CDC) partnered with
Malawi’s Ministry of Health (MOH) and the Lighthouse Trust, the largest provider of ART in
Malawi, to integrate hypertension screening and treatment into existing PEPFAR-funded HIV
care clinics. The Lighthouse Trust provides services to 25,000 PLHIVs of all ages and plays a
pivotal role in piloting service delivery models, introducing curricula on behalf of the national
HIV program to build capacity. It has its own procurement mechanism, which facilitated and
ensured the availability of antihypertensive medications.
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Ethical oversight
The investigation followed the guidelines of the United States Department of Health and
Human Services regarding protection of human participants. The study protocol was reviewed
according to the CDC, the Malawi MOH, and the Lighthouse Trust human participants review
process and was determined to be nonresearch.
Health systems strengthening approach
The integrated HIV and hypertension screening and management program was implemented
using a health systems strengthening approach and leveraging the public health approach,
which was successfully employed for the global HIV response [10]. According to WHO, health
systems consist of 6 building blocks that reflect the basic functions they should carry out
regardless of how they are organized: service delivery; health workforce; information; medical
products, vaccines, and technologies; financing; and leadership and governance (stewardship)
[11]. This framework was developed to address health inequalities worldwide.
The key elements of a successful hypertension management program reach beyond clinical
care delivery and require agreement and engagement from public health leaders, governments,
and healthcare providers, as well as broad policies to support integration with HIV care. The
main areas of our focus were policy, systems strengthening, innovation, education, and moni-
toring/evaluation (Table 1). Ensuring the consistent availability of low-cost, high-quality medi-
cations by improving existing supply chains or developing new procurement methods is
paramount [12]. As consistent access to medications was available at our sites, we focused
attention to optimal hypertension care delivery (Table 1) for low-resource settings [13].
The Lighthouse HIV-hypertension integrated model
We initiated a pilot program at 2 high-volume HIV clinics operated by the Lighthouse Trust in
Lilongwe, Malawi, as a demonstration project to inform modifications to our integrated hyper-
tension and HIV model and to identify challenges that warrant consideration. The aims of the
project were to (1) integrate hypertension screening and treatment in HIV care clinics, (2)
optimize hypertension treatment outcomes using standardized hypertension treatment proto-
cols and cohort monitoring, and (3) create a reproducible and scalable hypertension manage-
ment model that is cost-effective and can be used to inform national scale-up and other
chronic disease care models.
We encountered significant design and policy issues, which included the development of
standardized hypertension treatment protocols specific to the HIV population and consistent
with the Malawi Standard Treatment Guidelines, establishment of an adequate referral net-
work for complicated and resistant cases, and consensus on the need for routine laboratory
screening and cardiovascular disease risk assessment in the context of limited resources.
Below, we discuss each of these issues in more detail and explain the rationale for our deci-
sion-making process.
Developing treatment guidelines
In developing standardized treatment protocols, drug-drug interactions between antihyper-
tensive medications and ART warrant careful consideration. We aimed to minimize the num-
ber of patients likely to encounter significant interaction with non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based or protease inhibitor (PI)-based regimens, as in SSA
virtually all regimens in use include one or the other. In Malawi, the standard treatment guide-
lines recommend thiazide diuretics as first-line treatment for hypertension and calcium
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Table 1. Recommended elements for successful hypertension and human immunodeficiency virus (HIV) management integration.
Category Recommended elements Considerations for the HIV-infected
population
Used in Malawi hypertension-HIV program
Policy Population-level interventions (sodium
reduction)
National clinical guidelines
Guidelines that consider drug
interactions for hypertension treatment
Developed algorithms for hypertension
treatment that would minimize interactions
with antiretrovirals
System strengthening Service delivery:
Standardized assessment
Simplified management protocols
Blood pressure measurement devices
CVD risk estimation
Task shifting
Training
Clinical mentorship
Supply chain:
Improved medication procurement and sustained
availability
Access to fixed-dose combination medications
Community engagement:
Linkage to care
Community health workers
Leveraging existing infrastructure/systems
Benefit of angiotensin-converting
enzyme inhibitors
Leverage HIV medication supply chain
improvements
Enhanced adherence to complicated
regimens to treat HIV and co-
morbidities
Enhance PEPFAR service delivery
Service delivery:
Standardized assessment
Simplified management protocols
Blood pressure measurement devices
Task shifting
Training
Clinical mentorship
Supply chain:
Improved medication procurement and
sustained availability
Leveraging existing infrastructure/systems
Innovation Promotion and use of available technology
Electronic health records
mHealth
Telemedicine
Point-of-care laboratory testing
Improve availability of fixed-dosed combination
medications (e.g., medications with 2 active
ingredients)
Electronic health records
Education Community:
Mass media campaigns
Population-level health promotion
Clinical:
Training of healthcare workers during formal
education and in clinical practice
Culturally tailored educational materials
Leverage platforms for HIV education
to include chronic disease education
Clinical:
Training of healthcare workers during formal
education and in clinical practice
Culturally tailored educational materials
Monitoring/
evaluation
Tracking/indicators
Registries/cohort monitoring
Clinical feedback loop (chart reviews, line listing,
clinic-level control estimates, etc.)
Performance metrics for clinicians
Program evaluation using process and outcome
indicators
Track HIV-specific indicators (e.g.,
ART adherence)
Tracking/indicators
Registries/cohort monitoring
Clinical feedback loop (chart reviews, line
listing, clinic-level control estimates, etc.)
Performance metrics for clinicians
Program evaluation using process and outcome
indicators
Optimal hypertension
care delivery
Standardized screening and diagnosis using
certified and calibrated devices
Education about disease prevention and
counseling using culturally appropriate lifestyle
modifications
Standardized treatment protocols
Task shifting
Cohort monitoring
Standardized screening and diagnosis using
certified and calibrated devices
Education about disease prevention and
counseling using culturally appropriate lifestyle
modifications
Standardized treatment protocols
Task shifting
Cohort monitoring
Abbreviations: ART, antiretroviral therapy; CVD, cardiovascular disease; mHealth, mobile health; PEPFAR, President’s Emergency Plan for AIDS Relief. Cohort
monitoring: use of longitudinal patient registers or electronic medical records systems to regularly monitor progress and outcomes.
https://doi.org/10.1371/journal.pmed.1002523.t001
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channel blockers as second-line, with no special provisions for PLHIVs. Calcium channel
blockers may interact with NNRTIs and PIs, requiring dose adjustment [14], and angiotensin-
converting enzyme inhibitors (ACEIs) have been associated with anti-inflammatory effects
[15]. Given the potential drug interaction with calcium channel blockers and potential benefit
of ACEIs, we used ACEIs as second-line agents for the treatment of hypertension. To prevent
electrolyte imbalances, we suggested low-dose therapy of each class of medication with addi-
tion of another class rather than titration to maximum dose of current medication for patients
with uncontrolled BP. To support the expansion of this model to austere clinical sites, we have
developed a recommended algorithm for hypertension treatment for patients who are stable
on ART (Fig 1). Furthermore, we received permission for the modification of the hypertension
national guidelines from the Malawi Ministry of Health to accommodate necessary changes
for the treatment of hypertension among PLHIVs.
Referral network for those with complicated hypertension
Although the majority of hypertension patients will have essential hypertension, the possibility
of secondary and resistant hypertension should be assessed in patients with poor response to
antihypertensive therapy despite good adherence, in previously stable patients with worsening
Fig 1. Suggested algorithm for treatment of hypertension among human immunodeficiency virus (HIV)-infected persons.
ACEI, angiotensin-converting enzyme inhibitor; BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
https://doi.org/10.1371/journal.pmed.1002523.g001
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hypertension, and in patients with stage 3 hypertension (BP > 180/110) and significant target
organ disease [16]. The creation of a referral network, which is a type of integrated health ser-
vice, can facilitate directing persons to appropriate centers as indicated and is thus recom-
mended, as PLHIVs may have additional factors that warrant consideration by a specialist.
The use of technology, such as telemedicine, to access clinical specialists for those requiring
advanced assessment may also be considered for those communities or clinic populations with
inadequate access to care or in geographically isolated areas. We decided to refer patients to an
academic physician, who is a local expert in chronic diseases and thus a hypertension special-
ist, after evaluation by the clinic medical director, who is a certified physician.
Laboratory monitoring
Renal insufficiency, hypokalemia, and other complications may occur with the addition of
antihypertensive medications to ART and can be detected with laboratory screening. Labora-
tory monitoring for those on antihypertensive therapy may not routinely be performed in
SSA; however, it may be available for certain clinical indications, such as for patients who
develop signs and symptoms that suggest an electrolyte abnormality. If the clinical site is able
to conduct phlebotomy and separate serum for laboratory investigations and funding is avail-
able to pay for laboratory costs, chemistry panels, which include creatinine and potassium
measurements, should be conducted. Testing for creatinine and potassium is recommended at
baseline and at the 1-month follow-up visit, particularly for patients starting thiazide diuretics
and ACEIs. The need for routine laboratory monitoring is unclear and in extremely resource-
poor settings may be impractical to implement. Lack of access to laboratory monitoring should
not preclude screening and treatment of hypertension, as the number of patients who experi-
ence electrolyte abnormalities is small. Syndromic surveillance can be instituted to assess for
potential abnormalities [17]. In our project, we opted to forgo laboratory screening given the
challenges with implementation, lack of resources, and expected relatively low yield.
Cardiovascular disease risk assessment
HIV-specific factors such as low CD4+ cell counts and exposure to specific antiretrovirals
(ARVs) have been found to be independent risk factors for incident CVD and can increase
CVD risk as much as 50%–80% among PLHIVs [7]. Most CVD risk assessment tools tend to
underestimate CVD risk among PLHIVs [18]. Therefore, use of CVD risk assessment models
may fail to identify substantial numbers of PLHIVs with elevated CVD risk who could poten-
tially benefit from additional medical treatment. Nonetheless, in a low-resource setting, CVD
risk assessment can be used to prioritize treatment for those who would benefit most among
those PLHIVs who have achieved virologic suppression. We did not institute CVD risk assess-
ment, as further studies on CVD risk assessment among PLHIVs are warranted.
Implementation issues
We encountered key implementation issues, which included training of a cadre of healthcare
providers to screen for and treat hypertension among PLHIVs; integrating care for an addi-
tional disease entity without overwhelming the present infrastructure in terms of patient load
per provider, clinic wait times for patients, and quality of care; and developing routine moni-
toring and evaluation systems. The medical director provided regular monthly classroom
trainings to approximately 25 nurses and clinical officers who staffed the 2 clinics. These train-
ings were updated periodically to address issues that were of concern; for example, early in
implementation, we noted that patients diagnosed with hypertension were not filling their pre-
scriptions right away. These types of issues were addressed at weekly meetings with the
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medical director, and solutions were incorporated into subsequent trainings. To avoid disrupt-
ing clinic flow and ensure a manageable workload, we used a phased screening approach by
gradually decreasing the age threshold of eligible persons. Process and outcome indicators
developed for the project are summarized in Table 2. Registries can be used to generate perfor-
mance metrics for healthcare providers as well as inform clinical feedback to identify patients
who need follow-up care. Therefore, we developed a hypertension-specific module for the
Malawi electronic medical record system that provided screening and management prompts
for clinical decision support and facilitated data collection, including process indicators, and
analysis for ongoing program evaluation and quality of care improvement. We were particu-
larly concerned about the additional burden of HIV medications affecting adherence to ARVs;
therefore, we collected data on adherence, which was already being measured as part of the
HIV program.
Potential to improve HIV outcomes and access hard-to-reach
populations
Integrated service delivery and decentralization of care into primary health facilities and com-
munities can improve outcomes among PLHIVs. Expansion in ART coverage, improvement
in retention, and reduction in mortality have all been demonstrated in programs that have suc-
cessfully integrated HIV services into clinics for maternal, newborn, and child care as well as
tuberculosis treatment and opiate substitution therapy [19].
The integration of HIV and NCD management may particularly improve access to care for
adult males in SSA, a population that has remained elusive despite PEPFAR’s efforts to expand
ART [20]. Also, the integration of HIV and NCD services may reduce stigma associated with
Table 2. Example core process and outcome indicators for an integrated hypertension/human immunodeficiency virus (HIV) clinical management program exam-
ined at 6-month intervals.
Domain Type Description Numerator Denominator
Hypertension
control
Outcome Percentage of HIV patients 18 to 85 years of
age with a diagnosis of HTN and whose
blood pressure was adequately controlled
(<140/90) during the measurement period
Patients from the denominator with last
blood pressure measurement with systolic
blood pressure less than 140 mm Hg and the
diastolic blood pressure less than 90 mm Hg
All patients 18 to 85 years of age with a
diagnosis of HTN during the
measurement period who received
treatment for at least 3 months
Clinical quality Process Percentage of HIV hypertensive patients
aged 18 to 85 years with a blood pressure
reading of greater than 140/90 mm Hg who
were treated as outlined in the standardized
treatment protocol
Number of patients aged 18 through 85 years
and with hypertension and blood pressure
greater than 140/90 mm Hg who received
lifestyle modification and/or treatment
Number of hypertensive patients aged 18
through 85 years and with blood pressure
greater than 140/90 mm Hg
Clinical quality Process Percentage of electronic health record alerts
with a documented repeat blood pressure at
same visit if the first reading is above 140/90
mm Hg
Number of documented repeat blood
pressure readings at the same visit if the first
reading is above 140/90 mm Hg
Number of electronic health record alerts
indicating first reading is above 140/90
mm Hg
Clinical quality Process Percentage of treated hypertensive patients
with acceptable ART adherence (>95%)
Number of hypertensive patients with ART
adherence above a specified threshold
Number of HIV patients with HTN on
antihypertensive medications
Clinical quality Outcome Percentage of HIV/HTN patients lost to
follow-up from care and treatment
Number of HIV/HTN patients lost to follow-
up from care and treatment
Number of HIV/HTN patients alive and
on treatment
Healthcare
delivery
Cost Resources used by HIV patients with
hypertension during the measurement
period
Total standard cost and service frequency
counts for all services, which accounts for
service usage, for which the organization has
paid or expects to pay for the eligible
population during the treatment period,
reported by age, gender, and risk group
HIV patients 18 through 85 years of age
with a diagnosis of hypertension
Abbreviations: ART, antiretroviral therapy; HTN, hypertension.
Detailed cost parameters are not provided as they may vary across programs
https://doi.org/10.1371/journal.pmed.1002523.t002
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HIV, especially if these clinics eventually serve the general uninfected population [20]. A key
to improving access to ART and HIV outcomes may be to use the platforms that have been
developed for HIV care to build health systems that are available to all, thereby addressing the
double burden of HIV and NCDs effectively both at an individual as well as a population level.
Further research and evaluation of integrated care models are needed to inform efforts to use
limited healthcare resources effectively [21].
Discussion
The hypertension management model described here is consistent with the WHO’s framework
for health systems strengthening and considers the 6 building blocks that make up the health
system [11]. In addition, we promote the use of evidence-based tools and practices to improve
BP control.
In our demonstration project, at 12 months, of 29,359 individuals screened, 11% were
newly diagnosed with hypertension, and 85% of those with hypertension received treatment
per standardized protocols. Among persons with mild and moderate hypertension, BP control
rates were 38% and 30% after 6 months of treatment, respectively (Table 3). The additional
Table 3. Postimplementation program evaluation data for 2 Lighthouse Trust pilot sites in Lilongwe, Malawi,
February 2015 to June 2016.
Characteristic Total
Screening parameters
Number of persons screened† 29,359
Median age (IQR) 38 (32–45)
Male gender (%) 11,794 (39)
Diagnosis parameters
Number newly diagnosed with hypertension (%)‡ 3,448 (11)
Mild (SBP 140–159 or DBP 90–99) 1,619 (47)
Moderate (SBP 160–179 or DBP 100–109) 514 (15)
Severe (SBP 180 or DBP 110) 1,315 (38)
Treatment parameters
Number of hypertensive patients started on treatment or given lifestyle advice (%) 2,915 (85)
Number of all hypertensive patients on pharmacologic treatment for hypertension (%)ǁ 1,681 (49)
Control parameters
Of those on treatment for 3 months, number with normal blood pressure at last visit (%) 240 (22)
Of those on treatment for 6 months, number with normal blood pressure at last visit (%) 229 (26)
Adherence parameters
Number of hypertensive patients on treatment with at least 95% antiretroviral adherence 1,165 (80)
Number of patient without hypertension with at least 95% antiretroviral adherence 20,073 (79)
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
A phased approach was used at the Martin Preuss Clinic; therefore, the program was considered fully operational in
June 2015, and the evaluation period extended to 12 months from this date to June 2016.
†All patients were screened with an automated sphygmomanometer.
‡The definition of a new diagnosis of hypertension (HTN) was based on Malawi Standard Treatment Guidelines
(fourth edition): SBP 140 mm Hg or DBP 90 mm Hg measured on 2 consecutive visits or severe HTN
(SBP 180 mm Hg or DBP 110 mm Hg) on a single visit.
ǁProvision for treatment: all persons with moderate or severe HTN were eligible for treatment. For those with mild
HTN, only lifestyle modifications were suggested unless the individual had one cardiovascular disease (CVD) risk
factor (current smoker, diabetes mellitus [DM], history of CVD, or history of CVD in a first-degree relative).
https://doi.org/10.1371/journal.pmed.1002523.t003
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drug burden for hypertension control did not affect adherence to HIV medications. We did
not see any electrolyte abnormalities among persons prescribed antihypertensive medications
during the course of the project. This project successfully integrated hypertension screening
and management into routine HIV service delivery at 2 Lighthouse Trust HIV clinics; how-
ever, expansion within Malawi to government-funded sites is challenging because of the
inconsistent supply of medications for these types of facilities. Program evaluation is currently
underway.
Site-specific program costs associated with this add-on intervention will provide an esti-
mate of the average treatment cost per patient, and program cost-effectiveness analysis will
help assess whether the health return attributable to the intervention may be justified. Such
cost-effectiveness information may be useful in advocating for replication of the model among
civil society stakeholders and global policy makers, potentially leading to expanded public
health impact through the SSA region. Consistent access to medications for hypertension was
available at our sites, which may not be the case in many clinics, so this model is generalizable
to clinics with similar infrastructure in place. Hypertension and HIV integrated care will need
continued investments in supply-chain management because stock-outs of antihypertensive
medications commonly occur for the publicly funded clinics in Malawi. In Malawi, these
drugs are offered free of charge; however, this creates challenges for public health officials who
need to distribute limited resources to a number of programs, especially as support for HIV
medications starts to shift from PEPFAR to national ministries. Innovative approaches to pay-
ing for medications should be sought. For example, regional procurement mechanisms may
reduce overall costs, with bulk procurement rendering medications more available and afford-
able [12]. In addition, we were not able to implement care for comorbidities such as diabetes
given limited resources and staff. Finally, training a cadre of healthcare workers to provide
both chronic multidisease and HIV care may pose distinct challenges given limited numbers
of available personnel.
We hope that this program will help to inform the larger effort to improve health systems
and integrate HIV and NCD services for improved care. As outlined in the NCD global action
plan, this project directly relates to the priority action of member states to examine opportuni-
ties for HIV-NCD care integration not only to manage NCDs more effectively but also to
enhance the care of PLHIVs as they age and live longer due to improve ART coverage through-
out the world [22].
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